BridgeMD
New treatment option for Hypertriglyceridemia Induced Acute Pancreatitis
Official title Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis
ClinicalTrials.gov ID: NCT07388420
What this study is testing
What is Evolocumab 140 MG/ML [Repatha]?
Evolocumab 140 MG/ML [Repatha] is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for hypertriglyceridemia induced acute pancreatitis.
Also referred to as Dietary adjustments, Fibrates.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The severity of hypertriglyceridemia induced acute pancreatitis (HTG-AP) is closely related to the serum triglyceride (TG) levels. The higher the TG levels, the greater the risk of developing severe acute pancreatitis (SAP).
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Age 18\~75 years
- Patients with HTG-AP
- Mixed hyperlipidemia
- Sign the informed consent form
You likely can't join if
- Patients who have received lipid-lowering drugs or blood purification treatment
- Patients who have used evolocumab within one month before admission
- Patients who are accompanied by diseases that can seriously affect the survival
- Patients who have participated in the clinical research of other drugs within one month
- Patients who are pregnant or breastfeeding
- Patients with allergic asthma, allergic urticaria, eczema, and those who have a clear history of multiple drug and food allergies
See the full eligibility criteria
- Age 18\~75 years
- Patients with HTG-AP
- Mixed hyperlipidemia
- Sign the informed consent form
- Patients who have received lipid-lowering drugs or blood purification treatment
- Patients who have used evolocumab within one month before admission
- Patients who are accompanied by diseases that can seriously affect the survival
- Patients who have participated in the clinical research of other drugs within one month
- Patients who are pregnant or breastfeeding
- Patients with allergic asthma, allergic urticaria, eczema, and those who have a clear history of multiple drug and food allergies
- Other circumstances that researchers consider not suitable for participation in this study
The study team makes the final eligibility decision.
Where it's taking place
- Shenyang, Liaoning, China
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shenyang, Liaoning, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.